<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02341521</url>
  </required_header>
  <id_info>
    <org_study_id>OC000459/018/14</org_study_id>
    <nct_id>NCT02341521</nct_id>
  </id_info>
  <brief_title>Evaluation of Metabolic Profile of OC000459</brief_title>
  <official_title>An Evaluation of the Plasma and Urine Pharmacokinetics of Parent Compound and a Metabolite of OC000459 in Healthy Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atopix Therapeutics, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Simbec Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Atopix Therapeutics, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open label study in 9 male and 9 female healthy subjects to determine the pharmacokinetics&#xD;
      of parent compound and metabolite after eight days of dosing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include 9 male and 9 female healthy subjects. Following informed consent and&#xD;
      satisfactory screening, each will be dosed for seven consecutive days on an outpatient basis&#xD;
      with OC000459 50 mg daily taken before breakfast. On the seventh day, subjects will report to&#xD;
      the clinical unit. Following an overnight fast, blood samples will be drawn for baseline&#xD;
      safety and pharmacokinetic measurements and a urine specimen will be obtained for urinalysis&#xD;
      and baseline metabolite measurements and subjects will be dosed with 50 mg OC000459. Blood&#xD;
      samples will then be drawn at selected intervals for 120 hours post dosing and will be&#xD;
      analysed for OC000459 parent compound and its metabolite. Urine collections will be obtained&#xD;
      over the same period to determine the excretion of the metabolite and parent compound in&#xD;
      urine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolite</measure>
    <time_frame>Day 8</time_frame>
    <description>Metabolite AUC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parent compound</measure>
    <time_frame>Day 8</time_frame>
    <description>Parent compound AUC</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>OC000459 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OC000459 50 mg daily for 8 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OC000459</intervention_name>
    <description>Taken orally for 8 days</description>
    <arm_group_label>OC000459 50 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male and female subjects, any racial group&#xD;
&#xD;
          2. Aged 18-55 years inclusive&#xD;
&#xD;
          3. Able to comply with the protocol&#xD;
&#xD;
          4. Subjects with a Body Mass Index (BMI) of 21-28 (BMI = Body weight (kg) / (Height (m)2)&#xD;
&#xD;
          5. Subjects with no clinically significant abnormal serum biochemistry, haematology and&#xD;
             urine examination values within 21 days of the first dose&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A history of gastrointestinal disorder likely to influence drug absorption&#xD;
&#xD;
          2. Receipt of any medication including over the counter preparations and vitamins within&#xD;
             14 days of the first study day with the exception of paracetamol up to a maximum of 2&#xD;
             g daily&#xD;
&#xD;
          3. Evidence of clinically significant renal, hepatic, cardiovascular or metabolic&#xD;
             dysfunction&#xD;
&#xD;
          4. A history of drug or alcohol abuse&#xD;
&#xD;
          5. Inability to communicate well with the investigator (i.e., language problem, poor&#xD;
             mental development or impaired cerebral function)&#xD;
&#xD;
          6. Participation in a clinical study within 3 months of the first dose of study drug.&#xD;
             Subjects will be checked against The Over Volunteering Prevention System (TOPS)&#xD;
&#xD;
          7. Donation of 450 mL or more blood within 60 days of the first dose of study drug&#xD;
&#xD;
          8. A history of hypersensitivity and/or idiosyncrasy to any of the test compounds or&#xD;
             related drugs or excipients employed in this study&#xD;
&#xD;
          9. Pregnancy or lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salvatore Febbraro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Simbec Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Simbec Research</name>
      <address>
        <city>Merthyr Tydfil</city>
        <state>Wales</state>
        <zip>CF48 4DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>January 14, 2015</study_first_submitted>
  <study_first_submitted_qc>January 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2015</study_first_posted>
  <last_update_submitted>May 22, 2015</last_update_submitted>
  <last_update_submitted_qc>May 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

